LAKE FOREST, Ill. 10/18/2005 06:00 AM GMT (TransWorldNews)
NeoPharm, Inc. (Nasdaq:NEOL) today announced the date and time for its regularly-scheduled quarterly conference call to discuss corporate developments and financial highlights for the third quarter ended September 30, 2005.
During the call, Ronald G. Eidell, President and Chief Executive Officer, and Larry Kenyon, Chief Financial Officer, are expected to discuss:
-- Corporate results for the third quarter ended September 30,
-- PRECISE trial update
The conference call will be held on:
Tuesday, November 1, 2005 at 11:00 a.m. Eastern/8:00 a.m. Pacific
Domestic: 866-831-6247, passcode 11200980
International: 617-213-8856, passcode 11200980
Audio replays will be available through November 8, 2005.
Domestic: 888-286-8010, passcode 23290099
International: 617-801-6888, passcode 23290099
The live call and replay will also be available via webcast at www.neophrm.com.
About NeoPharm, Inc.
NeoPharm, Inc., based in Lake Forest, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a portfolio of cancer compounds in various stages of development. Additional information can be obtained by visiting NeoPharm's Website at www.neophrm.com.
Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to, progress and outcomes of clinical trials of the Company's drug product candidates, financial projections, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, developing, testing, obtaining regulatory approval for, producing and marketing of the Company's drug and non-drug compounds, uncertainty regarding the ability of licensees of our drugs, to obtain necessary foreign drug approvals or to adequately develop foreign markets, uncertainty regarding the availability of third party production capacity, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.
CONTACT: NeoPharm, Inc.
Paul Arndt, 847-887-0800 x 2342
SOURCE: NeoPharm, Inc.